Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Ziprasidone HCl hydrate (CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist that is licensed for the treatment of schizophrenia, has antipsychotic activity.
Targets |
Rat 5-HT2A ( Ki = 0.42 nM ); Rat 5-HT1A Receptor ( Ki = 3.4 nM ); Rat D2 Receptor ( Ki = 4.8 nM )
|
---|---|
ln Vitro |
Ziprasidone hydrochloride monohydrate (0-500 nM, 150 seconds) blocks wild-type hERG currents [2]. Cell Viability Assay[2] Cell Line: HEK-293 Cell Concentration: 0-500 nM Incubation Time: 150 sec Results: Blocks wild-type hERG current (IC50 = 120 nm) in a voltage- and concentration-dependent manner.
|
ln Vivo |
Ziprasidone hydrochloride monohydrate (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, lower physical activity levels, higher resting energy expenditure, and increased thermogenesis in the cold [3] . Animal model: 8-week-old female Sprague-Dawley rats, weighing 200 to 250 g[3] Dosage: 20 mg/kg Administration method: oral gavage; 20 mg/kg; once a day; 7-week results: significant weight loss (P = 0.031), had lower levels of physical activity (P = 0.016), had higher resting energy expenditure (P < 0.001), and showed greater thermogenic capacity when cold (P < 0.001).
|
References |
[1]. Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48(3):229-237.
[2]. Zhi Su, et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol. 2006 Jan 12;71(3):278-86. [3]. Subin Park, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012 Jun;61(6):787-93. |
Molecular Formula |
C21H24CL2N4O2S
|
---|---|
Molecular Weight |
467.409
|
Exact Mass |
466.1
|
Elemental Analysis |
C, 53.96; H, 5.18; Cl, 15.17; N, 11.99; O, 6.85; S, 6.86
|
CAS # |
138982-67-9
|
Related CAS # |
Ziprasidone; 146939-27-7; Ziprasidone-d8; 1126745-58-1; Ziprasidone hydrochloride;122883-93-6; Ziprasidone mesylate trihydrate; 199191-69-0
|
Appearance |
Solid powder
|
SMILES |
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl
|
InChi Key |
ZCBZSCBNOOIHFP-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
|
Chemical Name |
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrate;hydrochloride
|
Synonyms |
Ziprasidone HCl; Ziprasidone HCl hydrate; CP-88,059; CP-88,059-01; CP88059; CP-88059; CP 88059; CP88059 hydrochloride
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~25 mg/mL (~53.5 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.35 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1394 mL | 10.6972 mL | 21.3945 mL | |
5 mM | 0.4279 mL | 2.1394 mL | 4.2789 mL | |
10 mM | 0.2139 mL | 1.0697 mL | 2.1394 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.